SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

Corvus Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

138921115 (CUSIP Number)

September 21, 2021
(Date of Event Which Requires Filing of This Statement)

Check t	the appro	priate box to designate the rule pursuant to which this Schedule is filed:
		Rule 13d-1(b)
	ý	Rule 13d-1(c)
		Rule 13d-1(d)
		of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and formendment containing information which would alter the disclosures provided in a prior cover page.
	4 ("Act")	required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the
		Page 1 of 8

CUSIP No. 138921115				13G	Page 2 of 8 Pages			
1	1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)							
	TANG CAPITAL PARTNERS, LP							
2	CHECK THE APPROPRIA	TE BOX	IF A MEMBE	R OF A GROUP*	(a) □ (b) ý			
3	SEC USE ONLY							
4	CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE							
		5	SOLE VOTI	NG POWER				
SHARES BENEFICIALLY 3,736,184			SHARED VO 3,736,184	OTING POWER				
			0	OSITIVE POWER				
		8	SHARED DI 3,736,184	SPOSITIVE POWER				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,736,184							
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □							
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.8%							
12	TYPE OF REPORTING PERSON PN							

Page 2 of 8

CUSIP No. 138921115				13G	Page 3 of 8 Pages		
1	1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	TANG CAPITAL MANAG	EMENT,	LLC				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) (b) ý						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE						
		5	SOLE VOTI	NG POWER			
SHARES BENEFICIALLY 3,736,184			SHARED VO 3,736,184	OTING POWER			
			0	OSITIVE POWER			
		8	SHARED DI 3,736,184	SPOSITIVE POWER			
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,736,184						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.8%						
12	TYPE OF REPORTING PERSON OO						

Page 3 of 8

CUSIP No. 138921115				13G		Page 4 of 8 Pages	
	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	KEVIN TANG						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) □ (b) ý						
3	SEC USE ONLY						
•	CITIZENSHIP OR PLACE OF ORGANIZATION UNITED STATES						
	NUMBER OF SHARES	6		NG POWER			
EACH REPORTING PERSON WITH 0			SOLE DISPO	OSITIVE POWER SPOSITIVE POWER			
3,736,184							
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,736,184						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.8%						
12	TYPE OF REPORTING PERSON						

Page 4 of 8

Item 1(a). Name of Issuer:

Corvus Pharmaceuticals, Inc., a Delaware corporation (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

863 Mitten Road, Suite 102, Burlingame, CA 94010

Item 2(a). Name of Person Filing:

This Statement on Schedule 13G (this "Statement") is filed by Tang Capital Partners, LP ("Tang Capital Partners"); Tang Capital Management, LLC, the general partner of Tang Capital Partners ("Tang Capital Management"); and Kevin Tang, the manager of Tang Capital Management.

Item 2(b). Address of Principal Business Office or, if none, Residence:

4747 Executive Drive, Suite 210, San Diego, CA 92121

Item 2(c). Citizenship:

Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.0001 per share (the "Common Stock")

Item 2(e). CUSIP Number: 138921115

Item 3. Not applicable.

Item 4. Ownership.

(a) Amount Beneficially Owned:

Tang Capital Partners. Tang Capital Partners beneficially owns 3,736,184 shares of the Issuer's Common Stock.

Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

Tang Capital Management. Tang Capital Management beneficially owns 3,736,184 shares of the Issuer's Common Stock.

Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

Kevin Tang. Kevin Tang beneficially owns 3,736,184 shares of the Issuer's Common Stock.

Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

(b)	Percent of Class:							
		Capital Partners Capital Management Tang	8.8% 8.8% 8.8%					
(c)	Numbe	Number of shares as to which such person has:						
	(i)	sole power to vote or to direct the vote:	e:					
		Tang Capital Partners Tang Capital Management Kevin Tang	0 shares 0 shares 0 shares					
	(ii)	shared power to vote or to direct the vote:						
		Tang Capital Partners Tang Capital Management Kevin Tang	3,736,184 shares 3,736,184 shares 3,736,184 shares					
	(iii)	sole power to dispose or to direct the dispos	ition of:					
		Tang Capital Partners Tang Capital Management Kevin Tang	0 shares 0 shares					
	(iv)	position of:						
		Tang Capital Partners Tang Capital Management Kevin Tang	3,736,184 shares 3,736,184 shares 3,736,184 shares					
Own	ership o	f Five Percent or Less of a Class.						
		ent is being filed to report the fact that as of the e percent of the class of securities, check the f	e date hereof the reporting person has ceased to be the beneficial owner of following: \Box					
Own	ership o	f More than Five Percent on Behalf of Anot	her Person.					
Not a	pplicabl	e						
Iden	tification	n and Classification of the Subsidiary Which	h Acquired the Security Being Reported on by the Parent Holding Company.					
Not applicable.								
Iden	tification	n and Classification of Members of the Grou	աթ.					
Not a	pplicabl	e.						
Notic	e of Dis	solution of Group.						
Not a	pplicabl	e.						
			Page 6 of 8					
			ι αχε υ υι υ					

Item 5.

Item 6.

Item 7.

Item 8.

Item 9.

The percentages used herein are based on 42,421,159 shares of Common Stock outstanding as of August 2, 2021, as set forth in the

Issuer's Quarterly Report on Form 10-Q that was filed with the Securities and Exchange Commission on August 2, 2021.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:	September 22, 2021			
TANO	G CAPITAL PARTNERS, LP			
By:	Tang Capital Management, LLC, its General Partner			
By:	/s/ Kevin Tang Kevin Tang, Manager			
TANO	G CAPITAL MANAGEMENT, LLC			
By:	/s/ Kevin Tang Kevin Tang, Manager	<u>—</u>		
/s/ Kevin Tang Kevin Tang				
	Pag	e 8 of 8		

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, \$0.0001 par value per share, of Corvus Pharmaceuticals, Inc. and further agree to the filing of this Joint Filing Agreement as an exhibit thereto. In addition, each party to this Joint Filing Agreement expressly authorizes each other party to this Joint Filing Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.

Date: September 22, 2021

TANG CAPITAL PARTNERS, LP

By: Tang Capital Management, LLC

Its: General Partner

By: /s/ Kevin Tang

Name: Kevin Tang Title: Manager

TANG CAPITAL MANAGEMENT, LLC

By: /s/ Kevin Tang

Name: Kevin Tang Title: Manager

/s/ Kevin Tang

Name: Kevin Tang